Elacridar-hydrochloride-GF120918A-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEElacridar hydrochlorideCat. No.: HY-50880CAS No.: 143851-98-3Synonyms: GF120918A分式: CHClNO分量: 600.1作靶點: P-glycoprotein作通路: Membrane Transporter/Ion Channel儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性

2、數(shù)據(jù)體外實驗 DMSO : 5 mg/mL (8.33 mM; Need ultrasonic)H2O : 0.1 mg/mL (insoluble)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.6664 mL 8.3319 mL 16.6639 mL5 mM 0.3333 mL 1.6664 mL 3.3328 mL10 mM - - -請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實驗 Elacridar hydrochloride is dissolved in deionized

3、water6.BIOLOGICAL ACTIVITY物活性 Elacridar hydrochloride (GF120918A)P-糖蛋抑制劑，在體內(nèi)外實驗中常作為具化合物。1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE戶使本產(chǎn)品發(fā)表的科研獻 Clin Cancer Res. 2018 Jan 15;24(2):383-394. Cell Death Dis. 2019 May 24;10(6):400. J. Mater. Chem. B. 2018 Oct. Int J Mol Sci. 2019 Mar 5;20(5). pii: E

4、1125. J Agric Food Chem. 2019 Feb 27;67(8):2350-2360.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Sane R, Mittapalli RK, Elmquist WF. Development and evaluation of a novel microemulsion formulation of elacridar to improve itsbioavailability. J Pharm Sci. 2013 Jan 18.2. Banks

5、tahl JP, Bankstahl M, Romermann K, et al. Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein andBcrp at the Blood-Brain Barrier: A Small-Animal PET and In-Vitro Study. Drug Metab Dispos. 2013 Jan 10.3. Sane R, Agarwal S, Elmquist WF. Brain distribution and bioavailability of

6、 elacridar after different routes of administration in the mouse.Drug Metab Dispos. 2012 Aug;40(8):1612-9.4. Tang SC, Lagas JS, Lankheet NA, et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancerresistance protein (ABCG2) and can be enhanced by oral elacrida

7、r and sunitinib coadministration. Int J Cancer. 2012 Jan 1;130(1):223-33.doi: 10.1002/ijc.26000.5. Kuppens IE, Witteveen EO, Jewell RC, et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar(GF120918) and oral topotecan in cancer patients. Clin Cancer Res. 2007 Ju

8、n 1;13(11):3276-85.6. Hong Xiao, et al. Polymeric nanovesicle as simultaneous delivery platform with Doxorubicin conjugation and Elacridar encapsulation forenhanced treatment of multidrug-resistant breast cancer. J. Mater. Chem. B. 2018 Oct.McePdfHeightCaution: Product has not been fully validated for medical applications.Fo